How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
34
IMRN Quote, Financials, Valuation and Earnings
Last price:
$0.83
Seasonality move
:
72.04%
Day range:
$0.80 - $0.87
52-week range:
$0.68 - $2.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.99x
P/B ratio:
1.52x
Volume:
26.2K
Avg. volume:
66K
1-year change:
-61.31%
Market cap:
$4.7M
Revenue:
$4.7M
EPS (TTM):
-$0.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMRN
Immuron Ltd.
|
-- | -- | -- | -- | $3.47 |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $18.94 |
|
MESO
Mesoblast Ltd.
|
$23M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMRN
Immuron Ltd.
|
$0.81 | $3.47 | $4.7M | -- | $0.00 | 0% | 0.99x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.14 | $12.00 | $56.8M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.70 | $9.50 | $393M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$6.00 | $18.94 | $68M | -- | $0.00 | 0% | 270.88x |
|
MESO
Mesoblast Ltd.
|
$16.99 | $35.00 | $2.2B | -- | $0.00 | 0% | 119.24x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMRN
Immuron Ltd.
|
-- | 0.969 | -- | 5.77x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.224 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.527 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.448 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 2.607 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMRN
Immuron Ltd.
|
-- | -- | -53.91% | -53.91% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Immuron Ltd. vs. Competitors
-
Which has Higher Returns IMRN or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Immuron Ltd.'s net margin of --. Immuron Ltd.'s return on equity of -53.91% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMRNImmuron Ltd.-- -- $6.4M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About IMRN or ATHE?
Immuron Ltd. has a consensus price target of $3.47, signalling upside risk potential of 326.85%. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 282.78%. Given that Immuron Ltd. has higher upside potential than Alterity Therapeutics Ltd., analysts believe Immuron Ltd. is more attractive than Alterity Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMRNImmuron Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is IMRN or ATHE More Risky?
Immuron Ltd. has a beta of 0.824, which suggesting that the stock is 17.587% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.114, suggesting its less volatile than the S&P 500 by 88.643%.
-
Which is a Better Dividend Stock IMRN or ATHE?
Immuron Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuron Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMRN or ATHE?
Immuron Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Immuron Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Immuron Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuron Ltd. is 0.99x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMRNImmuron Ltd.0.99x -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns IMRN or IMMP?
Immutep Ltd. has a net margin of -- compared to Immuron Ltd.'s net margin of --. Immuron Ltd.'s return on equity of -53.91% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMRNImmuron Ltd.-- -- $6.4M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About IMRN or IMMP?
Immuron Ltd. has a consensus price target of $3.47, signalling upside risk potential of 326.85%. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 251.85%. Given that Immuron Ltd. has higher upside potential than Immutep Ltd., analysts believe Immuron Ltd. is more attractive than Immutep Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMRNImmuron Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is IMRN or IMMP More Risky?
Immuron Ltd. has a beta of 0.824, which suggesting that the stock is 17.587% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.579%.
-
Which is a Better Dividend Stock IMRN or IMMP?
Immuron Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuron Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMRN or IMMP?
Immuron Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Immuron Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Immuron Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuron Ltd. is 0.99x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMRNImmuron Ltd.0.99x -- -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns IMRN or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Immuron Ltd.'s net margin of --. Immuron Ltd.'s return on equity of -53.91% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital IMRNImmuron Ltd.-- -- $6.4M KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About IMRN or KZIA?
Immuron Ltd. has a consensus price target of $3.47, signalling upside risk potential of 326.85%. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $18.94 which suggests that it could grow by 215.86%. Given that Immuron Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Immuron Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMRNImmuron Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is IMRN or KZIA More Risky?
Immuron Ltd. has a beta of 0.824, which suggesting that the stock is 17.587% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.474%.
-
Which is a Better Dividend Stock IMRN or KZIA?
Immuron Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuron Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMRN or KZIA?
Immuron Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Immuron Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Immuron Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuron Ltd. is 0.99x versus 270.88x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMRNImmuron Ltd.0.99x -- -- -- KZIAKazia Therapeutics Ltd.270.88x -- -- --
-
Which has Higher Returns IMRN or MESO?
Mesoblast Ltd. has a net margin of -- compared to Immuron Ltd.'s net margin of --. Immuron Ltd.'s return on equity of -53.91% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMRNImmuron Ltd.-- -- $6.4M MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About IMRN or MESO?
Immuron Ltd. has a consensus price target of $3.47, signalling upside risk potential of 326.85%. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 106%. Given that Immuron Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Immuron Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMRNImmuron Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is IMRN or MESO More Risky?
Immuron Ltd. has a beta of 0.824, which suggesting that the stock is 17.587% less volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.154, suggesting its more volatile than the S&P 500 by 115.386%.
-
Which is a Better Dividend Stock IMRN or MESO?
Immuron Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuron Ltd. pays -- of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMRN or MESO?
Immuron Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Immuron Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Immuron Ltd.'s price-to-earnings ratio is -- while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuron Ltd. is 0.99x versus 119.24x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMRNImmuron Ltd.0.99x -- -- -- MESOMesoblast Ltd.119.24x -- -- --
-
Which has Higher Returns IMRN or PPCB?
has a net margin of -- compared to Immuron Ltd.'s net margin of --. Immuron Ltd.'s return on equity of -53.91% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMRNImmuron Ltd.-- -- $6.4M PPCB-- -$0.00 -- -
What do Analysts Say About IMRN or PPCB?
Immuron Ltd. has a consensus price target of $3.47, signalling upside risk potential of 326.85%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Immuron Ltd. has higher upside potential than , analysts believe Immuron Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings IMRNImmuron Ltd.0 0 0 PPCB0 0 0 -
Is IMRN or PPCB More Risky?
Immuron Ltd. has a beta of 0.824, which suggesting that the stock is 17.587% less volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock IMRN or PPCB?
Immuron Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuron Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMRN or PPCB?
Immuron Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Immuron Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Immuron Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuron Ltd. is 0.99x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMRNImmuron Ltd.0.99x -- -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 48.74% over the past day.
Buy
73
ENPH alert for Feb 5
Enphase Energy, Inc. [ENPH] is up 38.57% over the past day.
Sell
25
MRCY alert for Feb 5
Mercury Systems, Inc. [MRCY] is down 22.24% over the past day.
